Background: Multitransfused thalassemic patients have high prevalence for HCV infection. In developing countries, HCV antibody is reported to be high in this group of patients. Objective: To see the prevalence of Hepatitis C in multitransfused Thalassemic patients. Methods: This cross-sectional observational study was carried out in children with B- Thalassemia from outpatients department of haemato oncology, Shishu Hospital, Dhaka during February 2015 to August 2015. After fulfillment of inclusion and exclusion criteria patients here enrolled in this study and an ID no. was tagged to each of them. The subject was informed detailed about the study and consent was taken. A checklist was used for interviewing the parents, children and recording of demographic information, findings of physical examination and laboratory investigation were collected and under strict aseptic conditions and were sent to the department of Pathology for labrotory tests. Complete Blood Count with film, Serum bilirubin, SGPT, Prothrombin time, Serum Albumin, HBSAG, Anti HCV, USG of hepato biliary system. Results: Anti HCV was found 11 (18.3%) of the study patients. The mean age was 7.4±3.09 years with ranged from 4 to 16 years. Male to female ratio was 1.5:1. More than three fourth (78.4%) patients came from middle class family. All patients were immunized, 39(65.0%) had jaundice and 20(33.9%) had consanguinity. Two third 40(66.7%) patients had hepatomegaly, followed by 10(16.7%) had Splenectomy. Majority (86.6%) patients had Hb% level between to 5-10 gm/dl. HBsAg positive was found in 4(6.7%) of the study patients. Anti HCV positive found in 11 (18.3 %) of multitransfused thalassemia patients. Regarding the history and physical examination, 10(90.9%) patients had jaundice in anti HCV positive and 29(59.2%) in anti HCV negative. Abdominal pain found 6(54.5%) in anti HCV positive and 7(14.3%) in anti HCV negative. Jaundice and abdominal pain were significantly higher in anti HCV positive cases and other were not statistically significant between two groups. The mean weight was 24.6±8.8 kg in positive group and 15.8±5.5 kg in negative group. Mean splenomegaly was 13.9±2.7 cm in positive group and 9.6±5.2 cm in negative group. Mean hepatomegaly was 12.9±2.9 cm in positive group and 9.4±5.2 cm in negative group. The weight, splenomegaly and Hepatomegaly were significantly (P0.05) between two groups. The mean S.bilirubin was 2.2±0.5 mg/dl in positive group and 1.5±1.1 mg/dl in negative group, which was significantly (P<0.05) higher in anti HCV positive cases. Conclusion: Anti HCV positive was found 18.3% in multitransfused thalassemic patients.